Company intelligence / Profile preview

PharmaMar

Colmenar Viejo, Madrid, Spain

Ownership: Public · PHM
Employees: ~500
Development stage: Other

Overview

PharmaMar has successfully commercialized several first-in-class marine-derived oncology drugs. Yondelis® (trabectedin) was the first approved marine-origin anticancer drug for soft tissue sarcomas and relapsed ovarian cancer. Aplidin® (plitidepsin) treats multiple myeloma. Zepzelca™/lurbinectedin received FDA accelerated approval for small cell lung cancer based on positive Phase II results. The company also develops RNAi-based therapies for retinal diseases in earlier stages of development.

Therapeutic areas: OphthalmologyOncology
Modalities: Small molecules (marine-derived compounds)RNAi therapeutics (for retina diseases)
Industry: Biotech

Drug pipeline

13 assets

trabectedin

Approved

12 more assets in the full pipeline.

Request access →

Partnerships

Notable partnerships with pharmaceutical companies for commercialization/distribution of their products globally; specifics not detailed in search results.

Financials

Market cap: $23.2B
Total revenue: $4B
Enterprise value: $23.6B

Beyond the preview

Go deeper on PharmaMar.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PharmaMar.

Explore the full profile